首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1673593

免疫球蛋白市場規模、佔有率及成長分析（按適應症、劑型、給藥途徑、最終用戶和地區）－2025-2032 年產業預測

Immunoglobulin Market Size, Share, and Growth Analysis, By Indication (Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID)), By Form (Liquid, Lyophilized), By Route of Administration, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年03月01日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年免疫球蛋白市場規模價值 164 億美元，預計將從 2024 年的 175.2 億美元成長到 2032 年的 296.5 億美元，預測期內（2025-2032 年）的複合年成長率為 6.8%。

受免疫相關疾病盛行率上升以及診斷和治療技術進步的推動，全球免疫球蛋白市場預計將經歷顯著成長。監管環境和不斷成長的醫療保健支出進一步推動了這一擴張。技術創新和研發投入的增加正在提高免疫球蛋白治療的品質和有效性。此外，新興市場，特別是亞太和拉丁美洲，提供了巨大的成長機會。這些見解表明免疫球蛋白市場前景光明，敦促行業相關人員優先考慮技術創新、擴大生產能力並探索市場滲透策略，以滿足對這些重要治療方法日益成長的需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司詳細資訊
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Grifols（Spain）
CSL Limited（Australia）
Octapharma（Switzerland）
Kedrion Biopharma（Italy）
Biotest AG（Germany）
LFB Group（France）
Shanghai RAAS Blood Products（China）
China Biologic Products Holdings（China）
Baxter International Inc.（USA）
Takeda Pharmaceutical Company（Japan）
Sanquin（Netherlands）
Bio Products Laboratory（UK）
Emergent BioSolutions（USA）
ADMA Biologics（USA）
Kamada Ltd.（Israel）
Green Cross Corporation（South Korea）
SK Plasma（South Korea）
Hualan Biological Engineering Inc.（China）
Beijing Tiantan Biological Products（China）
Shire Plc（UK）

結論和建議

簡介目錄

Product Code: SQMIG35G2149

Immunoglobulin Market size was valued at USD 16.4 billion in 2023 and is poised to grow from USD 17.52 billion in 2024 to USD 29.65 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global Immunoglobulin market is poised for considerable growth, fueled by the rising incidence of immunological disorders and advancements in diagnostic and therapeutic techniques. A supportive regulatory landscape and increasing healthcare expenditures further bolster this expansion. Innovations and heightened investment in research and development are enhancing the quality and effectiveness of Immunoglobulin therapies. Additionally, emerging markets, notably in the Asia-Pacific and Latin America regions, offer substantial opportunities for growth. These insights suggest a promising outlook for the Immunoglobulin market, encouraging industry stakeholders to prioritize innovation, scale up capacities, and explore market penetration strategies to satisfy the growing demand for these vital therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunoglobulin Market Segments Analysis

Global Immunoglobulin Market is segmented by Indication, Form, Route of Administration, End-User and region. Based on Indication, the market is segmented into Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain Barre Syndrome, Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN) and Others. Based on Form, the market is segmented into Liquid and Lyophilized. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intramuscular. Based on End-User, the market is segmented into Hospitals, Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Immunoglobulin Market

A significant driver of the global Immunoglobulin market is the rising incidence of immunological disorders. Immunoglobulins are essential for treating a variety of conditions, including primary immunodeficiencies, autoimmune diseases, and infectious diseases. The growing prevalence of these disorders, enhanced by better diagnostic methods and increased awareness, is driving the demand for Immunoglobulin therapies. Contributing factors include genetic susceptibility, environmental influences, and lifestyle shifts that lead to a higher occurrence of immunological issues worldwide. Moreover, improvements in healthcare infrastructure, greater access to medical services, and increasing healthcare spending are also pivotal in propelling the market's expansion.

Restraints in the Immunoglobulin Market

A major constraint faced by the global Immunoglobulin market is the steep cost associated with Immunoglobulin therapies. The intricate processes required for the production, purification, and storage of these therapies contribute to elevated manufacturing expenses, which in turn lead to higher prices for patients and healthcare systems. This financial barrier is particularly pronounced in developing nations where healthcare resources are limited and affordability is a critical concern. Additionally, reimbursement challenges and restricted insurance coverage further exacerbate the financial strain on individuals seeking these therapies. Consequently, it is vital to explore strategies aimed at minimizing production costs, fostering market competition, and enhancing the availability of affordable Immunoglobulin treatments to improve patient access and care.

Market Trends of the Immunoglobulin Market

The global Immunoglobulin market is witnessing a prominent trend characterized by a surge in the adoption of intravenous immunoglobulin (IVIG) therapy. This therapy, crucial for patients with immunodeficiency disorders, autoimmune diseases, and specific neurological conditions, has gained traction due to its proven efficacy and the heightened awareness of its therapeutic benefits among healthcare professionals and patients alike. Innovations in production technologies, enhanced product safety standards, and the broadening scope of IVIG indications are fueling this adoption. Concurrently, the rising incidence of immunological disorders and an aging population are further propelling the demand for Immunoglobulin products, solidifying IVIG therapy's pivotal role in modern medicine.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Patent Analysis

Global Immunoglobulin Market Size by Indication & CAGR (2025-2032)

Market Overview
Primary Immunodeficiency (PI)
Secondary Immunodeficiency (SID)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Guillain Barre Syndrome
Immune Thrombocytopenic Purpura (ITP)
Multifocal Motor Neuropathy (MMN)
Others

Global Immunoglobulin Market Size by Form & CAGR (2025-2032)

Market Overview
Liquid
Lyophilized

Global Immunoglobulin Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
Subcutaneous

Global Immunoglobulin Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Homecare
Others

Global Immunoglobulin Market Size & CAGR (2025-2032)

North America (Indication, Form, Route of Administration, End-User)
- US
- Canada
Europe (Indication, Form, Route of Administration, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Form, Route of Administration, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Form, Route of Administration, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Form, Route of Administration, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Grifols (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologic Products Holdings (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SK Plasma (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hualan Biological Engineering Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Tiantan Biological Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments